<DOC>
	<DOCNO>NCT02359864</DOCNO>
	<brief_summary>This study design assess safety toxicity/adverse event associate use low dose fractionate whole brain irradiation patient diagnose probable Alzheimer 's disease accord NINCDS-ADRDA criterion . As secondary goal establish whether intervention low dose whole brain irradiation might change recognize progression Alzheimer 's Disease . The investigator also collect information AMYViD Â® PET Scans determine correlation neurocognitive/quality life score change amyloid plaque size , number location .</brief_summary>
	<brief_title>Study Low Dose Whole Brain Irradiation Treatment Alzheimer 's Disease</brief_title>
	<detailed_description>An initial 15 patient enrol first treatment scheme ( 2 Gy x 5 fraction ) follow 12 month completion treatment ass safety toxicity/adverse event associate treatment . The second treatment arm use last patient first dose arm complete follow . At point patient # 16-30 enrolled second dose arm ( 10 daily fraction 2 Gy ) . A total 30 patient enrol follow 12 month assess safety toxicity/adverse event . In Arm 1 15 study participant enrol total Botsford Radiation Oncology Center William Beaumont Hospital ( Royal Oak Campus ) . Once total combine 15 patient enter Arm close . In Arm 2 15 study participant enrol total Botsford Radiation Oncology Center William Beaumont Hospital ( Royal Oak Campus ) . Once total combine 15 patient enter Arm close .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Criteria Eligibility ( All response must YES ) 1 . The patient least 55 year old 2 . The patient able complete MiniMental Examination ADASCog score sheet 3 . No previous history CNS Radiation 4 . The patient Rosen Modified Hachinski Ischemic Score &lt; 4 5 . Patient estimate survival great 12 month 6 . Mini Mental Status Exam Score ( MMSE ) 10 20 7 . A patient probable diagnosis Alzheimer 's disease base NINCDS ADRDA criterion MMSE score 10 20 Criteria Exclusion ( All response must NO ) 1 . Any previous history CNS radiation 2 . The patient history oncologic disease may mitigate ability receive low dose whole brain irradiation 3 . Evidence substance abuse ( alcohol/or drug dependence previous 12 month ( DSMIV criterion ) 4 . Presence subdural hygroma 's subdural hematoma 5 . Active / Recent ( within 3 month ) cerebral infection/hemorrhage 6 . Immuno compromise state 7 . Prior history seizure 8 . Hydrocephalus 9 . Dermatological skin disease scalp 10 . Patient take Alzheimer 's medication ( Exelon , Aricept , Namenda , Reminyl Epixa )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>